Drugs in Dev. Oncology
Undisclosed
Ireland 
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Stand Up To Cancer
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will provide SU2C-funded researchers access to two Jazz molecules and funds to support one or more research projects over three years. One of the projects would help explore clinical use of lurbinectedin in rare and hard to treat pediat...
Product Name : Zepzelca
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 10, 2021
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Stand Up To Cancer
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Asparaginase Erwinia Chrysanthemi
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Asparaginase Erwinia Chrysanthemi is a Enzyme drug candidate, which is currently being evaluated in clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
June 29, 2021
Lead Product(s) : Asparaginase Erwinia Chrysanthemi
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zanidatamab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zanidatamab is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Biliary Tract Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 08, 2020
Lead Product(s) : Zanidatamab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lurbinectedin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Small Cell Lung Carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 02, 2020
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CPX-351
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML
Details : CPX-351 is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 26, 2015
Lead Product(s) : CPX-351
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
